{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:15:35Z","timestamp":1789625735201,"version":"build-2803163510"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Gender-affirming hormone therapy modifies body composition and lean muscle mass in transgender persons. We sought to characterize the change in serum creatinine, other kidney function biomarkers, and GFR in transgender persons initiating masculinizing and feminizing gender-affirming hormone therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>We searched PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov from inception to September 16, 2020 for randomized controlled trials, observational studies, and case series that evaluated the change in serum creatinine, other kidney function biomarkers, and GFR before and after the initiation of gender-affirming hormone therapy in adult transgender persons. Two reviewers independently screened and abstracted data, and disagreements were resolved by a third reviewer. A random effects meta-analysis was performed to determine the change in outcomes over follow-up of 3, 6, and 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 4758 eligible studies, 26 met the inclusion criteria, including nine studies that recruited 488 transgender men and 593 women in which data were meta-analyzed. There was heterogeneity in study design, populations, gender-affirming hormone therapy routes, and dosing. At 12 months after initiating gender-affirming hormone therapy, serum creatinine increased by 0.15 mg\/dl (95% confidence interval, 0.00 to 0.29) in 370 transgender men and decreased by \u22120.05 mg\/dl (95% confidence interval, \u22120.16 to 0.05) in 361 transgender women. No study reported the effect of gender-affirming hormone therapy on albuminuria, proteinuria, cystatin C, or measured GFR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Gender-affirming hormone therapy increases serum creatinine in transgender men and does not affect serum creatinine in transgender women. The effect on gender-affirming hormone therapy on other kidney function biomarkers and measured GFR is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial registry name and registration number:<\/jats:title>\n                    <jats:p>Change in Kidney Function Biomarkers in Transgender Persons on Gender Affirmation Hormone Therapy\u2013A Systematic Review and Meta-Analysis, CRD42020214248<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.01890222","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T12:00:27Z","timestamp":1660651227000},"page":"1305-1315","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":56,"title":["The Effect of Gender-Affirming Hormone Therapy on Measures of Kidney Function"],"prefix":"10.2215","volume":"17","author":[{"given":"Emily","family":"Krupka","sequence":"first","affiliation":[{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Curtis","sequence":"additional","affiliation":[{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-0358","authenticated-orcid":false,"given":"Reid","family":"Whitlock","sequence":"additional","affiliation":[{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Askin","sequence":"additional","affiliation":[{"name":"University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Millar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada"},{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8853-7368","authenticated-orcid":false,"given":"Marshall","family":"Dahl","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Fung","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Michael Garron Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia B.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"},{"name":"Max Rady Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-2014","authenticated-orcid":false,"given":"Michael","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Population Health Research Institute, Hamilton Health Sciences\/McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2323-6521","authenticated-orcid":false,"given":"David","family":"Collister","sequence":"additional","affiliation":[{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"},{"name":"Max Rady Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Population Health Research Institute, Hamilton Health Sciences\/McMaster University, Hamilton, Ontario, Canada"},{"name":"Section of Nephrology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMcp1903650","article-title":"Care of transgender persons","volume":"381","author":"Safer","year":"2019","journal-title":"N Engl J Med"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(16)00684-X","article-title":"Global health burden and needs of transgender populations: A review","volume":"388","author":"Reisner","year":"2016","journal-title":"Lancet"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jsxm.2016.02.001","article-title":"Prevalence of transgender depends on the \u201ccase\u201d definition: A systematic review","volume":"13","author":"Collin","year":"2016","journal-title":"J Sex Med"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: An Endocrine Society Clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4239\/wjd.v11.i3.66","article-title":"Effects of gender-affirming hormone therapy on insulin resistance and body composition in transgender individuals: A systematic review","volume":"11","author":"Spanos","year":"2020","journal-title":"World J Diabetes"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"e12660","DOI":"10.1111\/and.12660","article-title":"Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: A meta-analysis","volume":"49","author":"Klaver","year":"2017","journal-title":"Andrologia"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"2054358120985379","DOI":"10.1177\/2054358120985379","article-title":"Providing care for transgender persons with kidney disease: A narrative review","volume":"8","author":"Collister","year":"2021","journal-title":"Can J Kidney Health Dis"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2215\/CJN.14471119","article-title":"Ensuring gender-affirming care in nephrology: Improving care for transgender and gender-expansive individuals","volume":"15","author":"Mohottige","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1740774507083567","article-title":"Meta-analysis of longitudinal studies","volume":"4","author":"Ishak","year":"2007","journal-title":"Clin Trials"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: A cohort study","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1161\/HYPERTENSIONAHA.119.13080","article-title":"Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults","volume":"74","author":"Connelly","year":"2019","journal-title":"Hypertension"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1210\/jc.2018-02138","article-title":"Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen","volume":"104","author":"van Velzen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/jbmr.3762","article-title":"Gender-affirming hormone treatment decreases bone turnover in transwomen and older transmen","volume":"34","author":"Vlot","year":"2019","journal-title":"J Bone Miner Res"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jsm.12571","article-title":"Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: Results from the European network for the investigation of gender incongruence","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1053\/j.ajkd.2018.04.023","article-title":"Biological variability of estimated GFR and albuminuria in CKD","volume":"72","author":"Waikar","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/ndt\/gft518","article-title":"Is there a difference in metabolic burden between men and women?","volume":"29","author":"Nitsch","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/ndt\/gfg317","article-title":"The rate of progression of renal disease may not be slower in women compared with men: A patient-level meta-analysis","volume":"18","author":"Jafar","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"f324","DOI":"10.1136\/bmj.f324","article-title":"Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: A meta-analysis","volume":"346","author":"Nitsch","year":"2013","journal-title":"BMJ"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/ndt\/gfw084","article-title":"Sex hormones in women with kidney disease","volume":"31","author":"Ahmed","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1530\/eje.1.02126","article-title":"The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals","volume":"154","author":"Bunck","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4158\/EP15950.OR","article-title":"Metabolic effects of hormone therapy in transgender patients","volume":"22","author":"Fernandez","year":"2016","journal-title":"Endocr Pract"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jcem.83.2.4574","article-title":"Effects of sex steroids on plasma total homocysteine levels: A study in transsexual males and females","volume":"83","author":"Giltay","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000135710","article-title":"Effects of sex steroids on the neurotransmitter-specific aromatic amino acids phenylalanine, tyrosine, and tryptophan in transsexual subjects","volume":"88","author":"Giltay","year":"2008","journal-title":"Neuroendocrinology"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1373\/jalm.2018.027078","article-title":"Common hormone therapies used to care for transgender patients influence laboratory results","volume":"3","author":"Humble","year":"2019","journal-title":"J Appl Lab Med"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"e25338","DOI":"10.1002\/jia2.25338","article-title":"Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: The iFACT study","volume":"22","author":"Hiransuthikul","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1210\/jc.2018-02253","article-title":"Medroxyprogesterone acetate in gender-affirming therapy for transwomen: Results from a retrospective study","volume":"104","author":"Jain","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1507\/endocrj.EJ13-0203","article-title":"Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder","volume":"60","author":"Kurahashi","year":"2013","journal-title":"Endocr J"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/j.1743-6109.2008.00909.x","article-title":"Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals","volume":"5","author":"Meriggiola","year":"2008","journal-title":"J Sex Med"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/bmj.1.5851.449","article-title":"Effect of oestrogen therapy on plasma and urinary levels of uric acid","volume":"1","author":"Nicholls","year":"1973","journal-title":"BMJ"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"e25405","DOI":"10.1002\/jia2.25405","article-title":"Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men","volume":"22","author":"Shieh","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"B36-20241015","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1373\/clinchem.2018.292730","article-title":"Impact of hormone therapy on laboratory values in transgender patients","volume":"65","author":"SoRelle","year":"2019","journal-title":"Clin Chem"},{"key":"B37-20241015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2265.1998.00396.x","article-title":"Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones","volume":"48","author":"van Kesteren","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B38-20241015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.maturitas.2017.10.012","article-title":"Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study","volume":"107","author":"Vita","year":"2018","journal-title":"Maturitas"},{"key":"B39-20241015","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1210\/jc.2007-2467","article-title":"Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons","volume":"93","author":"Yahyaoui","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B40-20241015","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1530\/EC-19-0272","article-title":"Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy","volume":"8","author":"Angus","year":"2019","journal-title":"Endocr Connect"},{"key":"B41-20241015","first-page":"484","article-title":"[Morbidity in transsexual patients with cross-gender hormone self-treatment]","volume":"113","author":"Becerra Fern\u00e1ndez","year":"1999","journal-title":"Med Clin (Barc)"},{"issue":"Suppl 6","key":"B42-20241015","article-title":"Altered TDF\/FTC pharmacology in a transgender female cohort: Implications for PrEP","volume":"21","author":"Cottrell","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"B43-20241015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.amjmed.2013.10.009","article-title":"Interpreting laboratory results in transgender patients on hormone therapy","volume":"127","author":"Roberts","year":"2014","journal-title":"Am J Med"},{"key":"B44-20241015","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1210\/jc.2012-1187","article-title":"Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy","volume":"97","author":"Van Caenegem","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B45-20241015","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1111\/j.1743-6109.2012.02876.x","article-title":"Long-term evaluation of cross-sex hormone treatment in transsexual persons","volume":"9","author":"Wierckx","year":"2012","journal-title":"J Sex Med"},{"key":"B46-20241015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1530\/EC-19-0196","article-title":"Change in grip strength in trans people and its association with lean body mass and bone density","volume":"8","author":"Scharff","year":"2019","journal-title":"Endocr Connect"},{"key":"B47-20241015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0021-9150(03)00090-X","article-title":"Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals","volume":"168","author":"Giltay","year":"2003","journal-title":"Atherosclerosis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.01890222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:22Z","timestamp":1786369462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.01890222"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.01890222","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"2022-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}